Clinical Trial

ALS, Lou Gehrig’s Disease Clinical Trial 20203126

[LCID Study Number: 20203126]

A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to compare masitinib in combination with riluzole versus placebo in combination with riluzole as treatment for Amyotrophic Lateral Sclerosis (ALS).

Disease/Condition: ALS, Lou Gehrig’s Disease

Department: Gastroenterology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email:

Primary Contact Phone: 781-744-2400

Clinical Trial Details

View NCT ID 03127267 on

Protocol #: 20203126

Principal Investigator(s): Doreen Ho

Study Coordinator(s): Tanya Fennell

Trial Phase: Sponsor Initiated Study Phase 3